Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Adjusted retreatment of polypoidal choroidal vasculopathy after combination therapy: results at 3 years.

Jeon S, Lee WK, Kim KS.

Retina. 2013 Jun;33(6):1193-200. doi: 10.1097/IAE.0b013e318276e096.

PMID:
23508074
2.

Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.

Lai TY, Lee GK, Luk FO, Lam DS.

Retina. 2011 Sep;31(8):1581-8. doi: 10.1097/IAE.0b013e31820d3f3f.

PMID:
21610566
3.

Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.

Ricci F, Calabrese A, Regine F, Missiroli F, Ciardella AP.

Retina. 2012 Jul;32(7):1280-8. doi: 10.1097/IAE.0b013e318236e835.

PMID:
22218148
4.

Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.

Gomi F, Sawa M, Wakabayashi T, Sasamoto Y, Suzuki M, Tsujikawa M.

Am J Ophthalmol. 2010 Jul;150(1):48-54.e1. doi: 10.1016/j.ajo.2010.02.008.

PMID:
20609707
5.

Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.

Kang HM, Koh HJ, Lee CS, Lee SC.

Am J Ophthalmol. 2014 Mar;157(3):598-606.e1. doi: 10.1016/j.ajo.2013.11.015. Epub 2013 Nov 22.

PMID:
24269378
6.

One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.

Cheng CK, Peng CH, Chang CK, Hu CC, Chen LJ.

Retina. 2011 May;31(5):846-56. doi: 10.1097/IAE.0b013e3181f84fdf.

PMID:
21317837
7.

Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy.

Gemmy Cheung CM, Yeo I, Li X, Mathur R, Lee SY, Chan CM, Wong D, Wong TY.

Am J Ophthalmol. 2013 Feb;155(2):295-304.e1. doi: 10.1016/j.ajo.2012.08.002. Epub 2012 Oct 27.

PMID:
23111181
8.

Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.

Sagong M, Lim S, Chang W.

Am J Ophthalmol. 2012 May;153(5):873-882.e2. doi: 10.1016/j.ajo.2011.09.031. Epub 2012 Jan 20.

PMID:
22265146
9.

Comparison of the effect of reduced-fluence photodynamic therapy with intravitreal bevacizumab and standard-fluence alone for polypoidal choroidal vasculopathy.

Fan NW, Lau LI, Chen SJ, Yang CS, Lee FL.

J Chin Med Assoc. 2014 Feb;77(2):101-7. doi: 10.1016/j.jcma.2013.10.012. Epub 2013 Dec 12.

10.

Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up.

Lee YA, Yang CH, Yang CM, Ho TC, Lin CP, Huang JS, Chen MS.

Am J Ophthalmol. 2012 Nov;154(5):872-880.e2. doi: 10.1016/j.ajo.2012.03.051. Epub 2012 Jul 24.

PMID:
22831838
11.

Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.

Moon SW, Kim MS, Kim ES, Yu SY, Kwak HW.

Ophthalmologica. 2011;225(3):169-75. doi: 10.1159/000323811. Epub 2011 Jan 27.

PMID:
21273795
12.

Three-year visual outcome of photodynamic therapy plus intravitreal bevacizumab with or without subtenon triamcinolone acetonide injections for polypoidal choroidal vasculopathy.

Sakai T, Ohkuma Y, Kohno H, Hayashi T, Watanabe A, Tsuneoka H.

Br J Ophthalmol. 2014 Dec;98(12):1642-8. doi: 10.1136/bjophthalmol-2014-305189. Epub 2014 Jul 22.

PMID:
25053762
13.

Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy.

Cho HJ, Koh KM, Kim HS, Lee TG, Kim CG, Kim JW.

Am J Ophthalmol. 2013 Sep;156(3):524-31.e1. doi: 10.1016/j.ajo.2013.04.029. Epub 2013 Jun 13.

PMID:
23769197
14.

Choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy in recurrent polypoidal choroidal vasculopathy.

Maruko I, Iida T, Oyamada H, Sugano Y, Ojima A, Sekiryu T.

Am J Ophthalmol. 2013 Sep;156(3):548-56. doi: 10.1016/j.ajo.2013.03.041. Epub 2013 Jun 28.

PMID:
23810474
15.

HALF-DOSE PHOTODYNAMIC THERAPY COMBINED WITH BEVACIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.

Lee JH, Lee WK.

Retina. 2015 Aug;35(8):1561-8. doi: 10.1097/IAE.0000000000000498.

PMID:
25768248
16.

Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation.

Saito M, Iida T, Kano M.

Retina. 2011 Sep;31(8):1589-97. doi: 10.1097/IAE.0b013e31820f4b21.

PMID:
21654347
17.

Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.

Wakabayashi T, Gomi F, Sawa M, Tsujikawa M, Nishida K.

Br J Ophthalmol. 2012 Mar;96(3):394-9. doi: 10.1136/bjo.2011.204123. Epub 2011 Jun 30.

PMID:
21719568
18.
19.

Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.

Sato T, Kishi S, Matsumoto H, Mukai R.

Am J Ophthalmol. 2010 Jun;149(6):947-954.e1. doi: 10.1016/j.ajo.2009.12.038. Epub 2010 Mar 26.

PMID:
20346441
20.

Two-year outcome of photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide for polypoidal choroidal vasculopathy.

Nakata I, Tsujikawa A, Yamashiro K, Otani A, Ooto S, Akagi-Kurashige Y, Ueda-Arakawa N, Iwama D, Yoshimura N.

Graefes Arch Clin Exp Ophthalmol. 2013 Apr;251(4):1073-80. doi: 10.1007/s00417-012-2137-y. Epub 2012 Aug 25.

Supplemental Content

Support Center